Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track EOCN with free AI briefings, catalyst countdowns, and dilution alerts.

EOCN · Galmed Pharmaceuticals Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$8.8M Cash, Jun 2026

11mo Cash Runway (est.)

+298% Share Count, 1 Year

Follow EOCN by email Get an email when EOCN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about EOCN, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Apr 2026 · Phase 1 · Recruiting · Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tabl
Registry primary completion date, not a results date
Jun 2025 · Phase 1 · Results Expected · Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets
Registry primary completion date, not a results date
Mar 2022 · Phase 1 · Results Expected · Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With
Registry primary completion date, not a results date
Jul 2021 · Phase 1 · Results Expected · A First-in-Human Study of Single and Multiple Doses of Amilo-5MER in Healthy Subjects
Registry primary completion date, not a results date
Aug 2020 · Phase 1 · Results Expected · An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Bal
Registry primary completion date, not a results date
Feb 2019 · Phase 1 · Results Expected · Comparison of Aramchol Concentrations With Once or Twice Daily Dosing
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Aramchol free acid	Nonalcoholic Steatohepatitis (NASH)	Phase 3 · NCT04104321	Suspended
Aramchol	Fatty Liver	Phase 2 · NCT02279524	Completed
Aramchol meglumine	Primary Sclerosing Cholangitis	Phase 2 · NCT06095986	Withdrawn
Nintedanib	Colorectal Cancer	Phase 2 · NCT01362361	Completed
amilo-5MER	Inflammatory Disease	Phase 1 · NCT05857215	Completed
Atorvastatin	Healthy	Phase 1 · NCT03760848	Completed

Also used in these trials (approved or third-party drugs, not EOCN's own candidates): Midazolam Hydrochloride.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

EOCN reported $8.8M in cash and short-term investments (as of Jun 30, 2026) and used about $2.4M/quarter in operations, an estimated runway of 11.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 65 · High

Cash runway 11 months +30
Going-concern doubt in the latest 20-F +15Management has concluded that there is substantial doubt about our ability to continue as a going concern, and the report of our independent registered public accounting firm contains an explanatory paragraph as to our ability to continue as a going concern, which could prevent us from obtaining new financing on reason 20-F, Mar 2026
Share count +298% in a year +20

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EOCN files for a raise →

Get the full EOCN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EOCN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z